Table 3.
Treatment modalities in patients with primary membranous nephropathy according to presence of anti-PLA2R ab
| Variable | Anti-PLA2R ab(+) | Anti-PLA2R ab(−) | P value |
|---|---|---|---|
| Patient (n) | 25 | 23 | |
| RAS blockers | 23 (92.0) | 22 (95.7) | 0.602 |
| Statin | 25 (100) | 17 (73.9) | 0.006 |
| Immunosuppression | 19 (76.0) | 4 (17.4) | < 0.001 |
| Steroid | 19 (76.0) | 4 (17.4) | < 0.001 |
| Cyclosporin | 14 (56.0) | 4 (17.4) | 0.006 |
| Mycophenolate mofetil | 5 (20.0) | 0 (0) | 0.023 |
| Tacrolimus | 2 (8.0) | 0 (0) | 0.166 |
Data are presented as number only or number (%).
Anti-PLA2R ab, anti-phospholipase A2 receptor antibody; RAS, renin-angiotensin system.